PCA
ALLO icon

Pallas Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Pallas Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6K Sell
11,844
-14,394
-55% -$31.6K ﹤0.01% 1008
2026
Q1 		$64K Buy
26,238
+13,223
+102% +$26.5K ﹤0.01% 820
2025
Q4 		$17.8K Buy
+13,015
New +$17.2K ﹤0.01% 881

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pallas Capital Advisors's ALLO Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Allogene Therapeutics (ALLO) stake by 55% in Q2 2026, selling an estimated $31.6K and leaving 11,844 shares worth $24.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1008.

Pallas Capital Advisors first reported a position in ALLO in Q4 2025 and has held it in 3 quarters since. The position peaked at $64K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Pallas Capital Advisors held 11,844 shares of Allogene Therapeutics worth $24.6K as of Q2 2026.
  • Pallas Capital Advisors sold 14,394 Allogene Therapeutics shares in Q2 2026, an estimated $31.6K.
  • Allogene Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1008 holding.
  • Pallas Capital Advisors first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pallas Capital Advisors's Allogene Therapeutics position peaked at $64K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.